In MacroGenics’ SOPHIA Phase III study in adults with metastatic HER2-positive breast cancer, the biopharmaceutical company’s Margenza plus chemotherapy failed to show a statistically significant advantage when compared to trastuzumab plus chemotherapy in the intent-to-treat population.
The Bill & Melinda Gates Foundation will make a $35 million equity investment in privately owned Exscientia Ltd. to fund the development of antiviral drugs including for the coronavirus, the Oxford-based drug developer said on Sept. 8.
Amgen announced new data from the pivotal NAVIGATOR Phase 3 trial demonstrating that tezepelumab reduced exacerbations and improved lung function and nasal symptoms in patients with severe, uncontrolled asthma and comorbid nasal polyps.
Shares of Adaptimmune Therapeutics skyrocketed after the company announced an agreement to develop and commercialize allogeneic cell therapies for cancer with Genentech.
The U.S. Food and Drug Administration placed a clinical hold on BioMarin Pharmaceutical’s BMN 307 Phearless Phase I/II study.
Novartis announced that after conducting an interim analysis from the CIRRUS-1 trial of CFZ533 (iscalimab), the company is discontinuing the study in kidney transplant patients.
Shares of Forte Biosciences plunged after announcing that a Phase II atopic dermatitis trial assessing the company’s lead pipeline candidate failed to demonstrate statistical significance in the primary endpoint.
Pfizer announced on Sept. 2 the dosing of the first patients in a Phase III trial assessing a single dose of the company’s investigational RSV bivalent prefusion F subunit vaccine candidate (RSVpreF) in adults ages 60 and older. One day earlier, Pfizer announced the initiation of a Phase II/III clinical study of 1,140 participants for an oral pill expected to be used in a broad population of Covid patients.
Investors Hand Disc Medicine $90 Million to Control Hematological Diseases Published: Sept. 2, 2021 By Heather McKenzie BioSpace A two-year-old biopharma company tackling rare blood diseases has received a […]
Japanese biopharmaceutical firm Takeda Pharmaceutical announced that the company’s drug candidate for leukemia failed to meet the primary endpoint in a late-stage study.
